Beerse, 2 November 2016 – Johnson & Johnson has announced today that Stef Heylen will be the new head of Janssen Pharmaceutica. He will succeed Tom Heyman, who has led the company successfully for eight years. Tom Heyman will still be active within Johnson & Johnson.
From 3 November, Stef Heylen will take over from Tom Heyman as head of Janssen Pharmaceutica. Officially, he will be given the positions of managing director and chairman of the management committee of Janssen Pharmaceutica N.V. (Ltd.). Stef Heylen is also chief operating officer of Janssen R&D and will combine that position in the future with his new position of managing director of Janssen Pharmaceutica. Tom Heyman will still be active within Johnson & Johnson and will work full time in his position of global head of the Johnson & Johnson development corporation (JJDC). Tom will also still be the chairman of the Janssen Pharmaceutica N.V. executive board.
Click here for the full press release.
You can consult our multimedia center for the biography and some pictures of Stef.
